Autoimmune Encephalitis Diagnosis: A Comprehensive Guide

Diagnosing autoimmune encephalitis (AE) accurately is crucial for effective treatment and improved patient outcomes. AE, a condition where the body’s immune system mistakenly attacks healthy brain cells, can present with a wide range of neurological and psychiatric symptoms, often mimicking other conditions. Therefore, a thorough diagnostic process is essential to differentiate AE from other possible illnesses and initiate appropriate treatment.

Experts in the field have developed specific autoimmune encephalitis criteria to aid healthcare professionals in making accurate diagnoses. This involves a detailed review of a patient’s symptoms, a comprehensive physical examination, and a series of diagnostic tests. The diagnostic approach focuses on identifying patterns of symptoms suggestive of AE and confirming the presence of antibodies that are targeting brain receptors. These antibodies are the hallmark of AE, disrupting normal brain function and leading to the observed symptoms.

Furthermore, diagnostic testing plays a vital role in excluding other conditions that may present with similar symptoms. Infections, other autoimmune disorders, and neurological conditions need to be carefully considered and ruled out to arrive at a definitive diagnosis of autoimmune encephalitis. It’s important to note that misdiagnosis can occur, highlighting the necessity for healthcare professionals to maintain a broad differential diagnosis and consider all potential conditions when evaluating patients with suspected AE.

Key Lab Tests for AE Medical Diagnosis

Laboratory tests are fundamental in the medical diagnosis of autoimmune encephalitis, primarily focusing on the detection of specific autoantibodies in the patient’s system. These antibodies, erroneously produced by the immune system, target proteins and receptors in the brain, causing the inflammation and neurological dysfunction characteristic of AE.

Antibody testing is typically conducted on both blood samples and cerebrospinal fluid (CSF). CSF, the fluid surrounding the brain and spinal cord, is often more sensitive for detecting central nervous system-specific antibodies. The collection of CSF is performed via a lumbar puncture, also known as a spinal tap. This procedure involves numbing the lower back and carefully inserting a thin, hollow needle to extract a small sample of CSF for laboratory analysis. Analyzing CSF allows for a more direct assessment of the immunological processes occurring within the central nervous system in cases of suspected AE.

The Role of Brain Imaging in AE Diagnosis

Magnetic Resonance Imaging (MRI) of the brain is an indispensable tool in the diagnostic workup for autoimmune encephalitis. MRI provides detailed images of the brain’s structure and can reveal abnormalities that may be indicative of AE or help exclude other neurological conditions that could be causing the patient’s symptoms. While MRI findings in AE can be variable and sometimes subtle, certain patterns can raise suspicion for the condition, such as inflammation in specific brain regions.

In addition to brain MRI, other imaging tests might be recommended to investigate the possibility of an underlying cancer that could be triggering the autoimmune response. Paraneoplastic autoimmune encephalitis is a subtype of AE where the immune system’s attack on the brain is initiated by a tumor elsewhere in the body. Therefore, depending on the clinical presentation and suspicion for a paraneoplastic syndrome, imaging studies to screen for cancer may be part of the diagnostic evaluation.

Electroencephalogram (EEG) for Assessing Brain Activity

An electroencephalogram (EEG) is another valuable diagnostic test used in the evaluation of autoimmune encephalitis. EEG measures the electrical activity of the brain using electrodes placed on the scalp. This test is particularly useful in detecting seizure activity, which is a common symptom of AE. Abnormal EEG patterns can support the diagnosis of AE and help differentiate it from other conditions that may cause similar neurological symptoms.

Furthermore, EEG can help assess the overall brain function and identify patterns of electrical activity that are characteristic of encephalitis. While EEG findings alone are not definitive for AE, when combined with clinical features, antibody testing, and brain imaging, it contributes to a more comprehensive diagnostic picture.

Comprehensive Treatment Strategies for Autoimmune Encephalitis

Treatment for autoimmune encephalitis is centered on modulating the immune system, which is mistakenly attacking the brain. If the AE is identified as paraneoplastic, meaning triggered by a tumor, the primary focus of treatment will be to diagnose and treat the underlying cancer. However, in most cases of AE, the treatment strategy involves immunotherapy to suppress the aberrant immune response.

Immunotherapy: The Cornerstone of AE Treatment

Immunotherapy aims to reduce the activity of the overactive immune system and alleviate inflammation in the brain. Several types of immunotherapy are utilized in AE treatment, often administered intravenously (IV) in a hospital setting, particularly in the initial acute phase.

Common first-line immunotherapies include:

• Methylprednisolone (Solu-Medrol): This is a high-dose corticosteroid given intravenously, typically for 3 to 7 days, to rapidly reduce inflammation.
• Intravenous Immunoglobulin (IVIg): IVIg is a concentrated solution of antibodies from healthy donors. It is administered intravenously over 2 to 5 days and helps to modulate the immune system.

Second-line treatment options are considered if the initial immunotherapy is not sufficiently effective or for long-term management. These include:

• Oral Corticosteroids: Following initial IV steroids, oral corticosteroids are often prescribed with a gradually decreasing dose (tapering) over weeks to months to maintain immune suppression.
• Plasma Exchange (Plasmapheresis): This procedure physically removes antibodies from the blood. During plasma exchange, the liquid part of the blood (plasma) containing the harmful antibodies is separated from blood cells. The blood cells are then returned to the body, which then produces new plasma.

For patients who do not respond to first and second-line immunotherapies, or for those requiring long-term immune suppression to prevent relapse, stronger immunosuppressant medications may be used:

• Rituximab (Rituxan, Truxima): This medication targets B cells, a type of immune cell that produces antibodies.
• Cyclophosphamide: This is a more potent immunosuppressant that can be used in severe or refractory cases.
• Tocilizumab (Actemra, Tofidence, Tyenne): This medication targets interleukin-6 (IL-6), an inflammatory cytokine, and may be used in certain types of AE.

The duration of immunotherapy and the specific medications used are tailored to each individual’s case, considering the severity of the condition, the specific type of AE, and the patient’s response to treatment. Once symptoms improve with immunotherapy, medication doses are gradually reduced (tapered) to minimize side effects while maintaining disease control. Long-term maintenance immunotherapy may be necessary in some cases to prevent relapses.

Supportive Therapies and Rehabilitation

In addition to immunotherapy, managing symptoms and complications associated with AE is crucial. This may include treatment for seizures, sleep disorders, movement problems, and psychiatric symptoms. Rehabilitation plays a vital role in recovery, especially if AE has affected cognitive functions, memory, speech, or motor skills. Occupational therapists, speech therapists, physical therapists, and mental health professionals are integral to the multidisciplinary care team, assisting patients in regaining function and improving their quality of life.

The prognosis for autoimmune encephalitis varies depending on the type of AE, the severity of the condition, and the promptness of diagnosis and treatment. Early diagnosis and treatment are associated with better outcomes and a higher likelihood of recovery. While many individuals achieve significant recovery, some may experience persistent mild to moderate symptoms, particularly related to cognition and behavior, even after treatment. Long-term follow-up and management are important to monitor for potential relapses and address any ongoing symptoms or complications.

Preparing for Your Medical Diagnosis Appointment

If you are experiencing symptoms suggestive of autoimmune encephalitis, seeking prompt medical attention is essential. Your healthcare team will likely include neurologists, specialists in brain and nervous system disorders. For less severe symptoms, starting with your primary care physician is a reasonable first step. They can then refer you to a neurologist or other specialists as needed.

To prepare for your appointment, consider the following:

What You Can Do:

• Symptom Journal: Keep a detailed record of your symptoms, including when they started, how often they occur, and what makes them better or worse. Note any symptoms that seem unrelated to the main concern.
• Medical History: Compile key personal and medical information, including past medical conditions, surgeries, family medical history, major stressors, and recent life changes.
• Medication List: Create a comprehensive list of all medications, vitamins, and supplements you are currently taking, including dosages.
• Questions for Your Doctor: Prepare a list of questions to ask your healthcare professional to ensure all your concerns are addressed.

Example Questions to Ask:

• What are the most likely causes of my symptoms?
• Are there other possible causes for my symptoms besides autoimmune encephalitis?
• What specific tests will I need to undergo?
• Is my condition likely to be short-term or long-lasting?
• What treatment options are available, and what do you recommend?
• Are there alternative treatment approaches?
• How will my other health conditions be managed in conjunction with this condition?
• Are there any activity restrictions I should follow?
• Should I consult with a specialist?
• Are there any educational brochures or websites you recommend for more information?

What to Expect From Your Doctor:

Your healthcare professional will ask you detailed questions to understand your symptoms and medical history. Be prepared to answer questions such as:

• When did your symptoms first appear?
• Are your symptoms continuous or intermittent?
• How severe are your symptoms?
• What factors seem to improve your symptoms?
• What factors appear to worsen your symptoms?

Open and honest communication with your healthcare team is vital for accurate diagnosis and effective management of autoimmune encephalitis. By actively participating in the diagnostic process and understanding your condition, you can work collaboratively with your medical team to optimize your treatment and recovery.

Print

References

1. Ropper AH, et al. Multiple sclerosis and other neuroimmunologic disorders. In: Adams and Victor’s Principles of Neurology. 12th ed. McGraw Hill; 2023. https://accessmedicine.mhmedical.com. Accessed Oct. 3, 2024.
2. Chen L, et al. Association between autoimmune encephalitis and epilepsy: Systematic review and meta-analysis. Seizure. 2021; doi:10.1016/j.seizure.2021.07.005.
3. Aminoff MJ, et al., eds. Nervous system complications of systemic viral infections. In: Aminoff’s Neurology and General Medicine. 6th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Oct. 3, 2024.
4. Jankovic J, et al., eds. Autoimmune encephalitis with antibodies to cell surface antigens. In: Bradley and Daroff’s Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Oct. 3, 2024.
5. Loscalzo J, et al., eds. Paraneoplastic neurologic syndromes and autoimmune encephalitis. In: Harrison’s Principles of Internal Medicine. 21st ed. McGraw Hill; 2022. https://accessmedicine.mhmedical.com. Accessed Oct. 3, 2024.
6. Ferri FF. Antibody-mediated autoimmune encephalitis. In: Ferri’s Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Oct. 3, 2024.
7. Goldman L, et al., eds. Encephalitis. In: Goldman-Cecil Medicine. 27th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed Oct. 3, 2024.
8. Encephalitis. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/encephalitis#. Accessed Oct. 3, 2024.
9. Trewin BP, et al. Immunotherapy in autoimmune encephalitis. Current Opinion in Neurology. 2022; doi:10.1097/WCO.0000000000001048.
10. Dalmau J, et al. Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis. https://www.uptodate.com/contents/search. Accessed Oct. 3, 2024.
11. Abboud H, et al. Autoimmune (including paraneoplastic) encephalitis: Management. https://www.uptodate.com/contents/search. Accessed Oct. 3, 2024.
12. What is AE? Autoimmune Encephalitis Alliance. https://aealliance.org/patient-support/what-is-ae/. Accessed Oct. 4, 2024.
13. Diagnosis. Autoimmune Encephalitis Alliance. https://aealliance.org/patient-support/diagnosis/. Accessed Oct. 4, 2024.
14. How to heal. Autoimmune Encephalitis Alliance. https://aealliance.org/patient-support/recovery/. Accessed Oct. 4, 2024.
15. Status epilepticus. Epilepsy Foundation. https://www.epilepsy.com/complications-risks/emergencies/status-epilepticus. Accessed Oct. 7, 2024.
16. Orozco E, et al. Autoimmune encephalitis criteria in clinical practice. Neurology Clinical Practice. 2023; doi:10.1212/CPJ.0000000000200151.
17. Dubey D, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology. 2018; doi:10.1002/ana.25131.
18. Kelly MJ, et al. Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis. JAMA Neurology. 2024; doi:10.1001/jamaneurol.2024.0126.
19. Lee ST, et al. Innovation and optimization in autoimmune encephalitis trials: The design and rationale for the phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO). Frontiers in Neurology. 2024; doi:10.3389/fneur.2024.1437913.
20. Xiong W, et al. Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug-resistant epilepsy. Annals of Clinical and Translational Neurology. 2024; doi:10.1002/acn3.52112.
21. Dubey D, et al. Randomized placebo-controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy. Annals of Neurology. 2020; doi:10.1002/ana.25655.
22. Morvan syndrome. Genetic and Rare Diseases Information Center. https://rarediseases.info.nih.gov/diseases/9766/x. Accessed Oct. 16, 2024.
23. Flanagan EP, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurology. 2023; doi:10.1001/jamaneurol.2022.4251.
24. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Oct. 23, 2024.